| The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study S de Groot, MPG Vreeswijk, MJP Welters, G Gravesteijn, JJWA Boei, ... BMC cancer 15, 1-9, 2015 | 258 | 2015 |
| Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial S de Groot, RT Lugtenberg, D Cohen, MJP Welters, I Ehsan, ... Nature communications 11 (1), 3083, 2020 | 219 | 2020 |
| Effects of short-term fasting on cancer treatment S de Groot, H Pijl, JJM van der Hoeven, JR Kroep Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019 | 132 | 2019 |
| Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013 … RT Lugtenberg, S de Groot, AA Kaptein, MJ Fischer, EMK Kranenbarg, ... Breast cancer research and treatment 185, 741-758, 2021 | 48 | 2021 |
| Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer … S de Groot, A Charehbili, HWM van Laarhoven, AL Mooyaart, ... Breast Cancer Research 18, 1-11, 2016 | 38 | 2016 |
| Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer SC Hagenaars, S de Groot, D Cohen, TJA Dekker, A Charehbili, ... International journal of cancer 149 (5), 1181-1188, 2021 | 36 | 2021 |
| Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01) S De Groot, LGM Janssen, A Charehbili, EM Dijkgraaf, V Smit, ... Breast cancer research and treatment 149, 461-466, 2015 | 27 | 2015 |
| Dutch Breast Cancer Research Group (BOOG). Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial S De Groot, RT Lugtenberg, D Cohen, MJP Welters, I Ehsan, ... Nat. Commun 11, 3083, 2020 | 24 | 2020 |
| Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy S de Groot, H Gelderblom, M Fiocco, JVMG Bovée, JJM van der Hoeven, ... OncoTargets and therapy, 2963-2970, 2017 | 21 | 2017 |
| Unraveling the resistance of IGF-pathway inhibition in Ewing sarcoma S de Groot, B Röttgering, H Gelderblom, H Pijl, K Szuhai, JR Kroep Cancers 12 (12), 3568, 2020 | 14 | 2020 |
| Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC … S de Groot, H Pijl, A Charehbili, S van de Ven, VT Smit, ... Breast Cancer Research 21, 1-9, 2019 | 8 | 2019 |
| on behalf of the Dutch Breast Cancer Research Group (BOOG). Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct … RT Lugtenberg, S de Groot, AA Kaptein, MJ Fischer, EMK Kranenbarg, ... Breast Cancer Res. Treat 185, 741-758, 2020 | 7 | 2020 |
| The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival D Houtsma, S de Groot, R Baak-Pablo, EMK Kranenbarg, CM Seynaeve, ... Scientific Reports 11 (1), 3249, 2021 | 6 | 2021 |
| Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with … A Charehbili, S De Groot, T Van Der Straaten, JJ Swen, H Pijl, ... Pharmacogenomics 16 (11), 1265-1274, 2015 | 6 | 2015 |
| Phase 1 study to evaluate the safety of reducing the prophylactic dose of dexamethasone around docetaxel infusion in patients with prostate and breast cancer RT Lugtenberg, S de Groot, D Houtsma, VO Dezentjé, AJE Vulink, ... Cancers 15 (6), 1691, 2023 | 3 | 2023 |
| Evaluation of a Modified Early Warning Score (MEWS) adjusted for COVID-19 patients (CEWS) to identify risk of ICU admission or death L Smid, L Osman, SM Arend, S de Groot, MGJ de Boer medRxiv, 2020.10. 22.20217539, 2020 | 3 | 2020 |
| DIRECT: a phase II/III randomized trial with dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2-negative breast cancer S Groot, MPG Vreeswijk, V Smit, JB Heijns, ALT Imholz, LW Kessels, ... | 3 | 2013 |
| Abstract P4-16-12: CARE: A pilot study of the effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in breast cancer patients S de Groot, MPG Vreeswijk, G Gravesteijn, J Boei, A Jochems, D Houtsma, ... Cancer Research 73 (24_Supplement), P4-16-12-P4-16-12, 2013 | 3 | 2013 |
| Abstract P1-15-20: DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04) S De Groot, RT Lugtenberg, MJ Welters, I Ehsan, MP Vreeswijk, VT Smit, ... Cancer Research 79 (4_Supplement), P1-15-20-P1-15-20, 2019 | 1 | 2019 |
| Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients S de Groot, LA Louwé, AIE Ramautar, JEA Portielje, AC Ogilvie, E Batman, ... Cancer Management and Research, 3931-3935, 2018 | 1 | 2018 |
Hein PutterProfessor of Medical Statistics, Leiden University Medical Center在 lumc.nl 的电子邮件经过验证
